Issue Date: December 3, 2012
Pfizer Venture Arm Invests In Rhythm
Rhythm, a Boston-based biotech firm, has raised $33 million in a second financing round. Pfizer Venture Investments chipped in $8 million as a new investor. To date, the nearly three-year-old company has raised $73 million. Rhythm will use the funding to advance small-peptide therapeutics that target metabolic diseases. Rhythm’s ghrelin agonist RM-131 is in Phase II clinical trials for treating gastrointestinal disorders. A melanocortin-4 receptor agonist, RM-493, is in Phase I trials for treating obesity and diabetes.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society